Any thoughts on Marcus reaction when mentioning the results of bex on leukemia. He seemed very happy with the results to date of how bex worked with this.
Was he playing up to the recent investors from the leukemia foundation?
Been here since 2018 and have no intention of selling but like sax, don't want.to see 50 million dilution.
I think they know that bex will have benefits for a wide range of cancers but my feeli g is they need to concentrate on a couple of big winners to generate income rather than try to find all the winners now and never get anything to market...
Thinking about what they said about future finances.
They are talking to possible partners but they are taking their time to see if its a good deal for the shareholder or if they can fo it alone.
Deciding factor is funding.
They need 50 million for next stage then 100 million for th e stage after that.
3 things come to mind
1. Sell.out and its payday for everyone
2. Partner up and the final payday may not be so big. (It may just be a exit plan for us small holders.
3. Raise the 150 million alone via placings and loans and grants and us listing..
(The issue I have with this is that we will be diluted alot)
On the other hand, markku and team have bought alot higher than we arr now but was that with free money granted to them or their own cash, which is still from wages paid via money from funding?
That's it...
Didn't catch some things and was typing as I went so some comments may be illegible...
But the presentation will be posted on the website soon
Traumakine
Tests are still on going with the US medical side for battlefield wounds.
Waiting for data to design a trial
Seeking us listing?
Expanding clinical group over there, interested in setting up regulatory work.. for FDS
Haven't said they will list on nasdaq but they have high interest there but being cautious as the US markets have been down.
But they are exploring this option
Bexmab timeliness
Planning to expand into US
Soluble clever 1
Good question he is keeping quite aboutATM to test it before fully understood
Spending H2 forecast to be less than H1
Dosing and frequency in mantins trial
Not far from optimal dosing to go to regulators to move on to next phase.
One cohort they give 1 dose a week and it's working well
1 saves life is calculated at 50,000 pound so times that by who bex can save gives the value of the company
Questions.
Surrounded by possible partners, discussions are on going but not gonna rush into anything but it's looking exciting
Looking at options for the next funding if it's better to get a partner or go it alone
He feels that the regulators will be happy with all their data to move on with further trials
He feels that the regulators will be happy with all their data to move on with further trials
Bexmab is being used to treat leukemia
Markku seemed very excited with this. That's why they got the funding for this
Biomarker data is above 90 which is excellent for predicting clinical benefits of bex
Over 80 is considered good
So they a very good chance of working out who bex will work on which is very important for phase 3 trials
I've submitted your questions.. let's see if they are answered :)
When you register they send a email link. That email link opens up on a countdown page that as I write this would be to start at 12 but it also says it starts at 11pm
I'm logged on waiting and see what happens